title: 2-weekly docetaxel: issues for clinical practice.
abstract: In the phase III trial comparing 2 docetaxel schedules (3-weekly versus 2-weekly) as first-line chemotherapy for CRPC, recently published in The Lancet Oncology, fewer serious adverse events, particularly hematologic toxicities, and longer times on treatment, in favor of the 2-weekly regimen are reported. (1,2,3.)
authors.affiliation: a Medical Oncology; Azienda Ospedaliera Universitaria Integrata (A.O.U.I.) ; University of Verona ; Verona , Italy.
authors.forename: F
authors.initials: F
authors.lastname: Massari
authors.forename: F
authors.initials: F
authors.lastname: Maines
authors.forename: E
authors.initials: E
authors.lastname: Bria
authors.forename: E
authors.initials: E
authors.lastname: Galligioni
authors.forename: O
authors.initials: O
authors.lastname: Caffo
authors.forename: G
authors.initials: G
authors.lastname: Tortora
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel
keywords: 3-weekly schedule; doxetaxel; mCRPC